Contact

Jeste li zdravstveni djelatnik?

Contact

Jeste li zdravstveni djelatnik?

JGL conquers the global market

1 min čitanja Objavljeno: 02.3.2013.

According to the most recent analysis of 200 biggest global generic pharmaceutical companies carried out by Plimsoll, British institute for industrial research and analysis based on 4-year financial statements, JGL is 140th in terms of total revenue and 89th according to the profitability indicator. Considering the global financial and economic crisis that has over the last few years led to a significant reduction of business and a lower profit growth of many analysed companies, this results is a major success.

According to the preliminary financial results for 2012, in 2012 JGL continued to enjoy success resulting from its investments in the development of new products and strengthening the portfolio on the existing markets, opening new markets and raising competence in the system so that the products delivered to customers in all markets would meet the set objectives.

During the previous year JGL enjoyed an 19% growth in the net sales, and the export rate in the overall company revenue amounted to 75%. In accordance with the basic strategic goal – globalization, today JGL is present in some 30 countries across Europe, the US and the former USSR, while the Russian market continues to be the strongest one. This is further corroborated by many awards that the company has received over the years as an exporter, among which the latest one is the Zlatna kuna plaque for the most successful company of the Primorje-Gorski kotar county in the large companies category, awarded in late 2012.

Today JGL is 62nd among 800 producers present in the Russian pharmaceutical market, and its main product, the Aqua Maris nasal spray is among top 50 of more than 10,000 products registered in the Russian market! JGL’s representative office in Russia has 163 employees, in 2012 it achieved approximately EUR 42 million in sales and it has some 30 registered products in various legislation categories. This result is achieved by “covering” only some 10% of the clients – pharmacists, general practitioners and specialists, and by focusing on several therapy groups – ear, throat and nose, gynaecology, dermatology and ophthalmology.